ライフサイエンスコーパス: approve

1 HIPAA compliant and institution review board approved.

2 f this article, a fourth biosimilar has been approved.].

3 From 2001 through 2010, the FDA approved 222 novel therapeutics (183 pharmaceuticals and

4 ed for 8 indications that had been initially approved 5 or more years prior.

5 Most FDA-approved adjuvants for infectious agents boost humoral b

6 ouble-blind, intraindividual comparison of 3 approved agents applied blindly at the investigator site

7 al feature found embedded in many clinically approved agents.

8 tional subcommittee for research animal care approved all in vivo procedures.

9 Methods This was an intuitional review board-approved and HIPAA-compliant retrospective review of 10

10 sive evaluation of 304 inhibitors, including approved and investigational agents, comparing ex vivo r

11 and tenofovir alafenamide has recently been approved, and we aimed to investigate the efficacy, safe

12 Food and Drug Administration-approved anti-human cytomegalovirus drugs mainly target

13 Treatment of PA14 with the FDA-approved anti-inflammatory drug mesalamine, which has re

14 N-acetylcysteine (NAC), an FDA-approved anti-mucolytic agent, is a possible new treatme

15 t gain and potential alternatives, currently approved anti-obesity medications and best practices to

16 a weakly basic, Food and Drug Administration-approved antibiotic recommended by the World Health Orga

17 ine and the rapid emergence of resistance to approved antibiotics, this group is being reconsidered.

18 Most of the FDA approved anticancer drugs are organic molecules, while m

19 of 106 US Food and Drug Administration (FDA)-approved anticancer drugs or compounds currently in clin

20 All FDA-approved antipsychotic drugs (APDs) target primarily dop

21 za infection and also determine which of the approved antiviral inhibitor drugs is likely to be the m

22 has already led to the discovery of two FDA-approved (antiviral) ProTides.

23 a long established vaccination programme and approved antivirals.

24 Approved ARLG projects involving gram-positive pathogens

25 class of synthetic inhibitors, very recently approved as antihyperglycemic drugs, opens new perspecti

26 d colleagues examine orphan-designated drugs approved between 2009 and 2015 in the United States.

27 ever, beyond BRCA1/2 mutations, there are no approved biomarkers for olaparib in high-grade serous ov

28 his review will focus on the current CE-mark approved bioresorbable scaffolds, their basic characteri

29 ardiovascular disease were more likely to be approved, but approval rates did not vary by patient low

30 tiveness of the Food and Drug Administration-approved BVS versus metallic EES in patients undergoing

31 Materials and Methods The study was approved by a research ethics committee, and participant

32 s had died and had brain autopsies that were approved by board-certified neuropathologists.

33 ations for active pharmaceutical ingredients approved by FDA and other regulatory agencies.

34 A number of injectable hydrogels are approved by FDA as surgery sealants, tissue adhesives, a

35 Materials and Methods The study was approved by institutional animal and human studies commi

36 sight committee, and animal experiments were approved by the administrative panel on laboratory anima

37 Materials and Methods This study was approved by the animal care committee.

38 diffusion (30/20-mug disk) test methods were approved by the CLSI Subcommittee on Antimicrobial Susce

39 rials and Methods This prospective study was approved by the ethics review board, and informed consen

40 Among 222 novel therapeutics approved by the FDA from 2001 through 2010, 32% were aff

41 Drugs and biologics approved by the FDA that mention TPPs are associated wit

42 ulature, GSCs, and GECs, using drugs already approved by the FDA, can reduce both tumor size and inva

43 100 small-molecule oncology drugs have been approved by the FDA.

44 D) that was "non-MRI-conditional" (i.e., not approved by the Food and Drug Administration for MRI sca

45 V vector expressing GM-CSF has been recently approved by the Food and Drug Administration for the tre

46 ognized as an immunosuppressant and has been approved by the Food and Drug Administration to treat re

47 Materials and Methods The study was approved by the GE Global Research Center Institutional

48 aterials and Methods The animal protocol was approved by the institutional animal care and use commit

49 rials and Methods This prospective study was approved by the Institutional Animal Care and Use Commit

50 Materials and Methods All experiments were approved by the institutional animal care and use commit

51 Materials and Methods The procedures were approved by the institutional animal care committee.

52 als and Methods This retrospective study was approved by the institutional board review; written info

53 Materials and Methods This study was approved by the institutional review board and compliant

54 This single-center, retrospective study was approved by the institutional review board and compliant

55 s and Methods Work with human stem cells was approved by the institutional review board and the stem

56 Materials and Methods This study was approved by the institutional review board, and all part

57 Materials and Methods This study was approved by the institutional review board, and written

58 Materials and Methods The study was approved by the institutional review board.

59 Materials and Methods This study was approved by the institutional review board.

60 s and Methods This HIPAA-compliant study was approved by the institutional review board.

61 als and Methods This retrospective study was approved by the institutional review board.

62 This HIPAA-compliant retrospective study was approved by the institutional review board; the requirem

63 ruary 2012 through July 2015 under protocols approved by the local animal studies committee and insti

64 ective cohort study were included, which was approved by the local ethics board and written informed

65 hods This prospective case-control study was approved by the local ethics committee and the research

66 Materials and Methods The study was approved by the local Ethics Committee, and all patients

67 Materials and Methods The study was approved by the local ethics committee.

68 pretation of prospectively acquired data was approved by the local ethics committee.

69 rials and Methods This prospective study was approved by the local ethics committees, and written inf

70 ials and Methods This case-control study was approved by the local research ethics committee.

71 Materials and Methods The study was approved by the local review board (NL42888.029.13).

72 Materials and Methods Protocols were approved by the office of biologic safety and institutio

73 s and Methods This HIPAA-compliant study was approved by the regional ethics committee.

74 Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA)

75 Studies of drugs approved by the U.S. Food and Drug Administration and co

76 tide, is the only membrane-active antibiotic approved by the U.S. Food and Drug Administration so far

77 iagnostic is a test for a specific biomarker-approved by the United States Food and Drug Administrati

78 itten informed consent, and the protocol was approved by the university institutional review board.

79 herapeutic value of all new cancer medicines approved by the US Food and Drug Administration (FDA) an

80 For oncology drugs that were approved by the US Food and Drug Administration (FDA) an

81 arket safety events among novel therapeutics approved by the US Food and Drug Administration (FDA), a

82 gen receptor modulators, which have not been approved by the US Food and Drug Administration (FDA), t

83 Romidepsin and pralatrexate were approved by the US Food and Drug Administration for pati

84 The list of kinase inhibitors that have been approved by the US Food and Drug Administration was revi

85 leotide-based drug (nusinersen/Spinraza) was approved by US Food and Drug Administration (FDA) in lat

86 rapeutic activity of over 5,000 pairs of FDA-approved cancer drugs against a panel of 60 well-charact

87 STK11-silenced lung cancer cells to the FDA-approved CDK4 inhibitor palbociclib.

88 y ivacaftor (VX-770; Kalydeco), a clinically approved CFTR potentiator.

89 ing to identify Food and Drug Administration-approved chemotherapeutic compounds possessing synergist

90 chemically similar to ICRF-187, a clinically approved chemotherapeutic that stabilizes an ATP-depende

91 es of the Food and Drug Administration (FDA)-approved compound Tacrolimus, blocks calcineurin's activ

92 Here we screened in an unbiased approach FDA-approved compounds with respect to Angpt-2 suppression i

93 otics structurally related to the clinically approved daptomycin.

94 data for all patients receiving commercially approved devices from 2012 through December 31, 2015, th

95 safety of U.S. Food and Drug Administration-approved devices.

96 r the entire duration of the study using the approved dosages in the patients' respective countries a

97 ere treated with omalizumab according to the approved dosing table.

98 Intravenous immunoglobulin (IVIG) is a FDA-approved drug containing IgG.

99 and cis-diols (such as mannitol, a safe FDA approved drug for diuresis) through particle size measur

100 Here, we report that the FDA approved drug hydralazine is a bona fide activator of th

101 In this study, we screened the FDA-approved drug library for agents that share significant

102 new dual-action compound related to the FDA-approved drug memantine, representing an uncompetitive/f

103 Adenosine is a Food and Drug Administration-approved drug, but very little is known about the effect

104 ntify intracellular kinase engagement by the approved drug, dasatinib.

105 at dasatinib, a Food and Drug Administration-approved drug, potently binds Hck with high selectivity.

106 tely 34%) Food and Drug Administration (FDA)-approved drugs and account for a global sales volume of

107 in gene expression in response to 1,309 FDA-approved drugs and bioactives (CMap).

108 argets of Food and Drug Administration (FDA)-approved drugs and it too proves to be highly effective.

109 ces, and the overlap between DrugCentral FDA-approved drugs and their presence in four different chem

110 ribose) polymerase, are the first clinically approved drugs designed to exploit synthetic lethality,

111 multiple pathophysiological features, and as approved drugs in wide human use could be considered for

112 ilarity clustering identified unexpected FDA-approved drugs that induced DNA damage, including clinic

113 identified four Food and Drug Administration-approved drugs that selectively affect viability of TSC-

114 hway that can be targeted by new and already approved drugs to treat fragile X patients.

115 Drug repurposing is the application of approved drugs to treat new indications.

116 re several clinical trials in which recently approved drugs with known activity in AITL are paired wi

117 lue in identifying promising combinations of approved drugs with potent anticancer activity for furth

118 linear combinations of ring systems from FDA approved drugs, up to three rings in length and up to fo

119 creening the NIH clinical collections of FDA-approved drugs, we identified tacrolimus (FK-506) as the

120 large-scale cell cycle profiling of 884 FDA-approved drugs.

121 al processes, are the major target class for approved drugs.

122 in vitro alone and in combination with other approved drugs.

123 Misoprostol, an FDA-approved EP4 agonist, conferred similar protection again

124 rently the only Food and Drug Administration-approved first-line therapy for patients with advanced h

125 resistance [PVR] >/=240 dynes.s.cm) who were approved for a POPH MELD exception between 2006 and 2014

126 The SMOOTHENED inhibitor vismodegib is FDA approved for advanced basal cell carcinoma (BCC), and sh

127 ivity in the nonhuman primate models already approved for another indication or for which there was e

128 ster transfer protein inhibitor has yet been approved for clinical use.

129 nts who were prescribed a PCSK9i, 47.0% were approved for coverage by the payer.

130 cord according to CPRD quality control, were approved for CPRD and Hospital Episodes Statistics linka

131 (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment.

132 vir (OBV/PTV/r + DSV) +/- ribavirin (RBV) is approved for hepatitis C virus (HCV) genotype 1 (GT1) tr

133 which was the first antibody-drug conjugate approved for human use by the FDA.

134 of the species found are listed or have been approved for listing in 2017 in the appendices of the Co

135 No therapeutics or vaccines are approved for MERS; thus, development of novel therapies

136 Although immunotherapies are approved for MIBC, the majority of patients fail to resp

137 ect-acting antiviral (DAA) therapy, recently approved for patients with decompensated cirrhosis (DC)

138 ule used in phase II and III studies and now approved for patients with unresectable or metastatic me

139 Five detected pesticides were not approved for plant protection use in the EU.

140 elinostat, and brentuximab vedotin have been approved for relapsed and refractory peripheral T-cell l

141 Sorafenib is a RAF inhibitor approved for several cancers, including hepatocellular c

142 As everolimus is approved for tamoxifen-resistant or relapsing estrogen r

143 I discuss biologic agents already approved for the management of allergic and respiratory

144 No therapeutic agent has been approved for the prevention or treatment of this disorde

145 Pazopanib is US FDA approved for the treatment of advanced soft tissue sarco

146 bition of FAO by re-purposing existing drugs approved for the treatment of heart disease may provide

147 rugs, antihypertensive drugs, hypnotic drugs approved for the treatment of insomnia [sleep aids], att

148 The latest drug to be approved for the treatment of irritable bowel syndrome-d

149 Of note, ruxolitinib, a JAK1/2 inhibitor approved for the treatment of MF, had no inhibitory acti

150 , is the first targeted biologic therapeutic approved for the treatment of moderate-to-severe persist

151 tumumab, a CD38-directed monoclonal antibody approved for the treatment of multiple myeloma.

152 Adalimumab was recently approved for the treatment of noninfectious intermediate

153 The 5-HT2CR agonist lorcaserin, clinically approved for the treatment of obesity, causes important

154 Bevacizumab is approved for the treatment of patients with progressive

155 Purpose Bevacizumab regimens are approved for the treatment of recurrent glioblastoma in

156 eted approach, natalizumab was the first mAb approved for the treatment of relapsing-remitting multip

157 ib, a Bruton tyrosine kinase (BTK) inhibitor approved for the treatment of several B-cell malignancie

158 lucagon-like peptide 1 (GLP-1), and has been approved for the treatment of type 2 diabetes (T2D) in c

159 s a sodium-glucose cotransporter-2 inhibitor approved for the treatment of type 2 diabetes.

160 iological drugs, with over 50 such molecules approved for therapeutic use and hundreds more currently

161 es in advanced clinical stages, including 48 approved for therapeutic use, were collected and used to

162 Daptomycin, although not currently approved for this indication, is frequently used for the

163 rtan/sacubitril, a combination drug recently approved for treating heart failure, inhibits stretch-in

164 ein 1 (PD-1) and its ligand PD-L1, have been approved for treating human cancers with durable clinica

165 HT2B and 5-HT2A agonist activities, which is approved for treating obesity.

166 oglobin mutant, hydroxyurea is the only drug approved for treatment by the US Food and Drug Administr

167 Sorafenib is the only chemotherapeutic approved for treatment of advanced hepatocellular carcin

168 The B2 receptor antagonist icatibant is approved for treatment of attacks of hereditary angioede

169 de, a long-acting GLP-1 receptor agonist, is approved for treatment of obesity; however, the mechanis

170 30% range, and no antivirals or vaccines are approved for use for treatment and prevention of SFTS.

171 irst-in-class Hedgehog-pathway inhibitor, is approved for use in adults with advanced basal-cell carc

172 lating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis.

173 disease progression, no inhibitors have been approved for use in humans.

174 treated with a broad-spectrum antiviral drug approved for use in Japan.

175 Doxorubicin (Dox) is approved for use in liposomal form for the treatment of

176 ute lymphoblastic leukemia (ALL) blasts, was approved for use in patients with relapsed or refractory

177 EBR/GZR is approved for use in patients with renal impairment and p

178 In March 2017, dupilumab was approved for use in the treatment of atopic dermatitis (

179 no statin has been formally evaluated in, or approved for, HoFH children.

180 Methods For this institutional review board-approved HIPAA-compliant retrospective study, adult pati

181 d Methods In this institutional review board-approved HIPAA-compliant retrospective study, picture ar

182 this binational, institutional review board-approved, HIPAA-compliant prospective study, 158 subject

183 ti-institutional, institutional review board-approved, HIPAA-compliant retrospective analysis of 92 p

184 and Methods This institutional review board-approved, HIPAA-compliant retrospective study of prospec

185 In an institutional review board-approved, HIPAA-compliant, prospective study from April

186 Panobinostat (pano) is an FDA-approved histone deacetylase inhibitor.

187 One of the most potent, the EPA approved Hybrid (Ca(++)/K(+) channel blocker), was studi

188 ancer trials of Food and Drug Administration-approved immunotherapy drugs and selected those reportin

189 Both palbociclib and ribociclib have been approved in combination with hormone-based therapy for t

190 l syndrome-diarrhoea is rifaximin, which was approved in May 2015.

191 non-small-cell lung cancer (NSCLC) have been approved in the past decade, but little is known about t

192 ceptor (GR) antagonist mifepristone has been approved in the U.S. for the treatment of selected patie

193 enofovir disoproxil fumarate (TDF), has been approved in the United States and Europe for treating ad

194 anaparoid access has been limited and is not approved in the United States; and argatroban is contrai

195 rase strand transfer inhibitor-based regimen approved in the USA and European Union for individuals a

196 inant factor H binding protein-based vaccine approved in the USA for prevention of meningococcal sero

197 g-G1 monoclonal antibody targeting PD-L1 and approved in the USA for the treatment of metastatic Merk

198 Only trials investigating agents with an approved indication of reperfusion therapy in STEMI (str

199 Clinically approved inhibitors of MBLs are currently unavailable as

200 (n = 2) onto the Institutional Review Board-approved investigation of (11)C-MET PET/CT.

201 The only approved JAK2 inhibitor for myelofibrosis is the dual JA

202 scanner to identify the known targets of FDA-approved kinase inhibitors based on templates involving

203 Since currently approved L-asparaginases are of bacterial origin, immuno

204 titumor therapeutic outcomes than clinically approved liposomal doxorubicin (Doxil) in HER2-overexpre

205 tiveness of the Food and Drug Administration-approved lower-dose ticagrelor regimen (60 mg twice dail

206 are still needed to successfully develop an approved male hormonal contraceptive and to identify lon

207 termined all US Food and Drug Administration-approved manufacturers for each formulation and strength

208 Although the currently approved medications can reliably reduce the viral load

209 t posttransplant, mortality in patients with approved MELD exceptions for POPH.

210 Passive immunotherapy is an approved method used to protect individuals against seve

211 The regulatory approved MicronJet600(R) (MicronJet hereafter) device wa

212 nist dehydroepiandrosterone (DHEA) as an FDA-approved model drug.

213 d (90)yttrium-ibritumomab tiuxetan, were FDA-approved more than a decade ago but have been little uti

214 vice Breast Screening Program), an ethically approved, multicenter, multireader, retrospective readin

215 Cys181 and have lower cytotoxicity than the approved NNRTI drugs efavirenz and rilpivirine.

216 ount given the excellent safety of currently approved nucleos(t)ide analogues.

217 other US Food and Drug Administration (FDA)-approved oncology drugs.

218 in trials of US Food and Drug Administration-approved oncology immunotherapy drugs with results poste

219 To date, AR-targeted drugs have been approved only for treatment of prostate cancer; however,

220 e safely given in combination with currently approved PAH therapies.

221 While CDK4/6 inhibitors are FDA approved (palbociclib) for treating advanced estrogen re

222 d and neck cancers who were treated with the approved PD1-targeting antibodies pembrolizumab or nivol

223 nitial PMA) and median number of supplements approved per device, by device type, and overall, strati

224 amilial amyloid polyneuropathy, there are no approved pharmacologic therapies shown to improve surviv

225 ays emphasis on biological evaluation of FDA approved photosensitizing agents as well as newly design

226 Targeting is achieved by coating FDA-approved PLGA-PEG NP with the peptide sequence RGD, whic

227 glycolic acid) (PLGA) is a biodegradable FDA approved polymer and widely used in drug and vaccine del

228 rates of claim reversal (failure to purchase approved prescription), delayed initiation (reversal wit

229 No approved prophylaxis or therapy exists for these toxicit

230 HIPAA-compliant, institutional review board-approved prospective blinded pilot study, patients under

231 thods This was an institutional review board-approved, prospectively conducted (written informed cons

232 al following an Food and Drug Administration-approved protocol.

233 irrhosis, in routine practice (all currently approved regimens were registered).

234 tation Council on Graduate Medical Education-approved residency and fellowship training programs.

235 HIPAA-compliant, institutional review board-approved retrospective cohort study, an institutional da

236 d Methods In this institutional review board-approved retrospective review of prospectively acquired

237 HIPAA-compliant, institutional review board-approved retrospective study included 51 patients (mean

238 ation of a U.S. Food and Drug Administration-approved serotonin agonist (lorcaserin) to septic rats g

239 ods SIESTA was an institutional review board-approved, single-center, prospective, randomized, parall

240 We then compared R-BIND to both FDA-approved small molecule drugs and RNA ligands without re

241 We also identified the approved small-molecule antifungal agent ciclopirox as a

242 Medication approved solely for ADHD treatment.

243 de (RK-10-Biotin) was tested against the FDA-approved SP263 clone on biopsied patient tissues.

244 and Methods This institutional review board-approved study included 125 women with invasive breast c

245 his retrospective institutional review board-approved study included 24 patients with prostate cancer

246 A single center IRB approved study included 874 patients.

247 institutional animal care and use committee-approved study was performed in C57BL6 mice (n = 20) and

248 ethods In this Animal Care and Use Committee approved study, 17 days after the injection of 2 x 10(6)

249 is retrospective, institutional review board-approved study, 41 pediatric patients (age range, 3-17 y

250 Institutional Animal Care and Use Committee-approved study, healthy rats received 20 intravenous inj

251 y included in this regional ethics committee-approved study.

252 is retrospective, institutional review board-approved study.

253 enrolled in this institutional review board-approved study.

254 e-based delivery of Ova using the clinically-approved subcutaneous immunotherapy (SCIT) route.

255 are no US Food and Drug Administration (FDA)-approved T cell therapeutics on the market, and FDA regu

256 omprehensive Cancer Network (NCCN) guideline-approved targeted drugs.

257 everal scenarios of resistance to clinically approved targeted inhibitors of the human EGF receptor f

258 enosine restricts the efficacy of clinically approved targeted therapies for commonly mutated BRAF(V6

259 There are no specifically approved targeted therapies for the most common genomica

260 ncers (TNBC) are highly aggressive, lack FDA-approved targeted therapies, and frequently recur, makin

261 ties for expansion of indications for use of approved targeted therapies.

262 screened for LTBI by the three commercially approved tests, namely, the tuberculin skin test (TST),

263 rements and first-principles calculations to approve the higher tendency of sulfur-rich lead chromate

264 y, 2017, the US Food and Drug Administration approved the blood infection marker procalcitonin for gu

265 Twenty years ago, Oregon voters approved the Death With Dignity Act, making Oregon the f

266 the Clinical Practice Guidelines Committee, approved the final endorsement.

267 April 2016, the Food and Drug Administration approved the first biosimilar monoclonal antibody (mAb),

268 s and Methods The institutional review board approved the study.

269 Omalizumab, a clinically approved therapeutic antibody, inhibits the interaction

270 ing hemorrhagic fever outbreaks for which no approved therapeutic exists.

271 There is no vaccine or other approved therapeutic.

272 There are no approved therapeutics for the treatment of dengue diseas

273 atment of multiple myeloma, with several FDA-approved therapeutics.

274 for HSCT have typically been failed by most approved therapies, have undergone multiple surgeries, a

275 ty in immunocompromised individuals, with no approved therapies.

276 e and economic burden for which there are no approved therapies.

277 ondrial protein Frataxin (FXN), which has no approved therapy and is an area in which biomarkers are

278 nase (JAK) inhibitor ruxolitinib is the only approved therapy for patients with symptomatic myelofibr

279 docetaxel (a US Food and Drug Administration-approved therapy) from prednisone and mitoxantrone and w

280 he absence of a Food and Drug Administration-approved therapy.

281 Methods The local institutional review board approved this HIPAA-compliant retrospective single-cente

282 iew boards of the four participating centers approved this HIPAA-compliant study.

283 s and Methods The Cancer Registry Regulation approved this retrospective study.

284 e institutional review boards of each center approved this retrospective, HIPAA-compliant, multicente

285 s and Methods The institutional review board approved this study.

286 study requirements imposed when PrEP was not approved through the regulatory system, which could have

287 consisting of the committee as a whole, was approved to develop a new Technical Standard on reportin

288 e suberoylanilide hydroxamic acid is already approved to treat cutaneous T-cell lymphoma, it could po

289 Up to now, approved treatment options are not available.

290 outbreak combined with the lack of available approved treatment options, there was strong motivation

291 gy (FA) is an increasing problem that has no approved treatment.

292 There are no FDA approved treatments available for NPC patients.

293 There are no approved treatments for Lassa fever, which is endemic to

294 han, systemic autoimmune disease with no FDA-approved treatments.

295 nyavirus families, for which there is no FDA-approved vaccine or therapeutic available, with the exce

296 ka virus (ZIKV) infection and the lack of an approved vaccine raise serious concerns regarding prepar

297 are important human pathogens for which FDA-approved vaccines do not exist and effective antiviral t

298 emergency in West Africa, there are still no approved vaccines or therapeutics for the treatment of a

299 As there are currently no approved vaccines or treatments for EBOV, a better under

300 nd two disease-modifying therapies have been approved, worldwide.